LB Pharmaceuticals to Participate in Upcoming September Investor Events
LB Pharmaceuticals schedules multiple investor conference appearances and virtual webcasts across September 2026, with replays available on its investor relations website.
Rhea-AI Summary
LB Pharmaceuticals (LBRX)/b) will present at several investor events in September 2026, including conferences hosted by Wells Fargo, H.C. Wainwright, and TD Cowen.The company will hold in-person 1x1 meetings at Wells Fargo’s 21st Annual Healthcare Conference on September 9 in Boston, virtual presentations and 1x1 meetings at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, and a virtual fireside chat during TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23. Webcasts and replays will be accessible via the Investors/Events section of LB Pharmaceuticals’ website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LBRX
In the Sep 4 session, LBRX gained 3.83%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Wells Fargo conference edition
- 21st Annual
- Healthcare Conference
- Wells Fargo meeting date
- September 9, 2026
- Boston investor meetings
- H.C. Wainwright conference edition
- 28th Annual
- Global Investment Conference
- H.C. Wainwright presentation time
- 10:00 a.m. ET
- September 14, 2026
- H.C. Wainwright meeting date
- September 14, 2026
- Virtual 1x1 investor meetings
- TD Cowen summit edition
- 6th Annual
- Novel Mechanisms in Neuropsychiatry Summit
- TD Cowen fireside chat time
- 2:30 p.m. ET
- September 23, 2026
- TD Cowen fireside chat date
- September 23, 2026
- Virtual investor event
Historical Context
-
Reported quarterly results, clinical updates, and a $51.6 million net loss.
-
Announced $150 million private placement financing with shares and pre-funded warrants.
-
Moved anticipated NOVA-2 topline results into the first half of 2027.
-
Granted an option to purchase 75,000 shares to a newly hired executive.
-
Appointed Christopher Zergebel as Senior Vice President of Clinical Operations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
1x1 investor meetings financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:
Wells Fargo 21st Annual Healthcare Conference
- 1x1 investor meetings on Wednesday, September 9, 2026, in Boston, MA
H.C. Wainwright 28th Annual Global Investment Conference
- Presentation will be available virtually at 10:00 a.m. ET on Monday, September 14, 2026
- Virtual 1x1 investor meetings on Monday, September 14, 2026
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
- Virtual fireside chat at 2:30 p.m. ET on Wednesday, September 23, 2026
The webcasts for the presentation and fireside chat will be available on the “Investors” page section under the “Events” section of the Company’s website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Media and Investor Contact:
Ellen Rose
erose@lbpharma.us
FAQ
What September 2026 investor conferences will LB Pharmaceuticals (LBRX) participate in?
LB Pharmaceuticals will participate in three investor events in September 2026: Wells Fargo’s 21st Annual Healthcare Conference on September 9, H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, and TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23.
When will LB Pharmaceuticals (LBRX) hold its Wells Fargo Healthcare Conference meetings?
LB Pharmaceuticals plans to hold 1x1 investor meetings at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, in Boston, Massachusetts.
What is the schedule for LB Pharmaceuticals’ H.C. Wainwright conference events in September 2026?
At H.C. Wainwright’s 28th Annual Global Investment Conference, LB Pharmaceuticals will have a virtual presentation at 10:00 a.m. ET on Monday, September 14, 2026, followed by virtual 1x1 investor meetings later that same day.
When is LB Pharmaceuticals’ TD Cowen virtual fireside chat scheduled?
The company’s virtual fireside chat at TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit is scheduled for 2:30 p.m. ET on Wednesday, September 23, 2026.
How can investors access LB Pharmaceuticals’ September 2026 conference webcasts and replays?
Webcasts of LB Pharmaceuticals’ presentation and fireside chat, along with archived replays, will be available on the company’s website in the “Investors” page under the “Events” section at https://ir.lbpharma.us/.